Extended Low-Dose Apixaban and Superficial Vein Thrombosis

JAMA Cardiology 2026 Open access

Read full text
Authors: Sina Rashedi, Mariana Becker Pfeferman, Arvind Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Junyang Lou, John R. Fanikos, Nicole D Porio, Lisa R. Rosenbaum
+7 more Piotr S. Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber, Behnood Bikdeli, Gregory Piazza
DOI: 10.1001/jamacardio.2026.0151
Cited by: 1
References: 6

Abstract

This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism ( HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Blood Coagulation and Thrombosis Mechanisms

Publication details

Journal / source
JAMA Cardiology
Publisher
American Medical Association (AMA)
Volume
11
Issue
5
Pages
478–478
Publication date
29 March 2026
Language
EN